Breast Cancer
Conference Coverage
VIDEO: Watson for Oncology offers electronic curbside consults in breast cancer
Andrew Norden, MD, describes how Watson for Oncology works, and how different versions of the Watson platform are being used in medicine...
Conference Coverage
VIDEO: Abemaciclib reduces Ki67 expression in early HR+/HER2– breast cancer
SAN ANTONIO – Abemaciclib, both alone and in combination with anastrozole, significantly reduced Ki67 expression vs. anastrozole monotherapy after...
Conference Coverage
Aromatase inhibitor effect on endothelial function may lead to CVD
Aromatase inhibitors appear to have a decremental effect on vascular endothelial function, which could contribute to cardiovascular disease.
Conference Coverage
VIDEO: No effect of BRCA status on overall outcomes in early-onset breast cancer
SAN ANTONIO – No difference in outcomes was seen among young BRCA gene mutation carriers and noncarriers with early stage invasive breast cancer...
Conference Coverage
No boost in pCR from neoadjuvant estrogen deprivation
Estrogen deprivation added to chemotherapy and dual HER2 inhibition did not improve pathologic complete responses, compared with chemotherapy...
Conference Coverage
VIDEO: No improvement in pCR with dual ER and HER2 inhibition
SAN ANTONIO
Conference Coverage
Optimal duration of extended AI therapy? Flip a coin
SAN ANTONIO – The optimal duration of aromatase inhibitor therapy following 5 years of endocrine therapy in postmenopausal women is still unknown...
Conference Coverage
Next-generation sequencing highlights evolution of ER+ breast cancer
The “genomic landscape” of resistant estrogen receptor–positive metastatic breast cancer differs significantly from that of ER+ primary breast...
Conference Coverage
VIDEO: Veliparib misses PFS endpoint, advances to phase III trial
SAN ANTONIO – Veliparib failed to significantly improve progression-free or overall survival when added to carboplatin and paclitaxel in patients...
Conference Coverage
Fulvestrant/everolimus improves PFS in HR+, HER2– advanced breast cancer
SAN ANTONIO – Adding everolimus to fulvestrant doubled median progression-free survival among postmenopausal women with hormone-receptor positive...
Conference Coverage
VIDEO: Investigator discusses fulvestrant/everolimus combo
SAN ANTONIO – Most women with hormone receptor–positive breast cancer treated with an aromatase inhibitor will eventually develop resistance to...